Acorah Software Products - Accounts Production 18.1.200 false true 31 December 2024 1 January 2024 false 1 January 2025 31 December 2025 31 December 2025 SC745604 Mr Jamie Hodgson Dr Daniel Galbraith Mr David Lawrence Dr Steven Powell true iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure SC745604 2024-12-31 SC745604 2025-12-31 SC745604 2025-01-01 2025-12-31 SC745604 frs-core:CurrentFinancialInstruments 2025-12-31 SC745604 frs-core:Non-currentFinancialInstruments 2025-12-31 SC745604 frs-core:PlantMachinery 2025-12-31 SC745604 frs-core:PlantMachinery 2025-01-01 2025-12-31 SC745604 frs-core:PlantMachinery 2024-12-31 SC745604 frs-core:SharePremium 2024-12-31 SC745604 frs-core:SharePremium 2025-12-31 SC745604 frs-core:ShareCapital 2025-12-31 SC745604 frs-core:RetainedEarningsAccumulatedLosses 2025-01-01 2025-12-31 SC745604 frs-core:RetainedEarningsAccumulatedLosses frs-core:PreviouslyStatedAmount 2024-12-31 SC745604 frs-core:RetainedEarningsAccumulatedLosses 2025-12-31 SC745604 frs-bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 SC745604 frs-bus:FilletedAccounts 2025-01-01 2025-12-31 SC745604 frs-bus:SmallEntities 2025-01-01 2025-12-31 SC745604 frs-bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 SC745604 frs-bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 SC745604 1 2025-01-01 2025-12-31 SC745604 frs-core:FurtherSpecificReserve1ComponentTotalEquity 2024-12-31 SC745604 frs-core:FurtherSpecificReserve1ComponentTotalEquity 2025-12-31 SC745604 frs-bus:Director1 2025-01-01 2025-12-31 SC745604 frs-bus:Director2 2025-01-01 2025-12-31 SC745604 frs-bus:Director3 2025-01-01 2025-12-31 SC745604 frs-bus:Director4 2025-01-01 2025-12-31 SC745604 frs-countries:EnglandWales 2025-01-01 2025-12-31 SC745604 2023-12-31 SC745604 2024-12-31 SC745604 2024-01-01 2024-12-31 SC745604 frs-core:CurrentFinancialInstruments 2024-12-31 SC745604 frs-core:Non-currentFinancialInstruments 2024-12-31 SC745604 frs-core:SharePremium 2024-12-31 SC745604 frs-core:ShareCapital 2024-12-31 SC745604 frs-core:RetainedEarningsAccumulatedLosses 2024-12-31 SC745604 frs-core:FurtherSpecificReserve1ComponentTotalEquity 2024-12-31
Registered number: SC745604
Glen Clova Scientific Limited
Unaudited Financial Statements
For The Year Ended 31 December 2025
Approved Accounting Limited
Glen Clova Scientific Limited
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—5

Page 1
Glen Clova Scientific Limited
Balance Sheet
As At 31 December 2025
Balance Sheet
Registered number: SC745604

| 2025 | 2024
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Tangible Assets | 4 |  | 283,034 |  | 135,551
|  |  | 283,034 |  | 135,551
CURRENT ASSETS
Debtors | 5 | 74,134 |  | 67,617 |
Cash at bank and in hand |  | 408,718 |  | 2,043,244 |
|  | 482,852 |  | 2,110,861 |
Creditors: Amounts Falling Due Within One Year | 6 | (200,531 ) |  | (82,912 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 282,321 |  | 2,027,949
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 565,355 |  | 2,163,500
Creditors: Amounts Falling Due After More Than One Year | 7 |  | (54,450 ) |  | -
NET ASSETS |  |  | 510,905 |  | 2,163,500
CAPITAL AND RESERVES
Called up share capital | 8 |  | 478 |  | 436
Share premium account |  |  | 3,765,374 |  | 3,010,293
Fair value reserve | 9 |  | 33,915 |  | -
Profit and Loss Account |  |  | (3,288,862 ) |  | (847,229 )
SHAREHOLDERS' FUNDS |  |  | 510,905 |  | 2,163,500

Page 1
Page 2
Glen Clova Scientific Limited
Balance Sheet (continued)
As At 31 December 2025
For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Mr Jamie Hodgson Director
18/06/2026

The notes on pages 3 to 5 form part of these financial statements.
Page 2
Page 3
Glen Clova Scientific Limited
Notes to the Financial Statements
For The Year Ended 31 December 2025
Notes to the Financial Statements
1. General Information
Glen Clova Scientific Limited is a private company, limited by shares, incorporated in England & Wales, registered number SC745604 . The registered office is Clydes Offices 2nd Floor, 48 West George Street, Glasgow, Scotland, G2 1BP.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Plant & Machinery | 3 - 5 years on cost

2.3. Leasing and Hire Purchase Contracts
Assets obtained under finance leases are capitalised as tangible fixed assets. Assets acquired under finance leases are depreciated over the shorter of the lease term and their useful lives. Assets acquired under hire purchase contracts are depreciated over their useful lives. Finance leases are those where substantially all of the benefits and risks of ownership are assumed by the company. Obligations under such agreements are included in the creditors net of the finance charge allocated to future periods. The finance element of the rental payment is charged to the profit and loss account so as to produce a constant periodic rate of charge on the net obligation outstanding in each period.
Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to the profit and loss account as incurred.
2.4. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
2.5. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 20 (2024: 19)
20 19
Page 3
Page 4
Glen Clova Scientific Limited
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2025
4. Tangible Assets

| Plant & Machinery
--- | ---
| £
Cost
As at 1 January 2025 | 146,826
Additions | 211,071
As at 31 December 2025 | 357,897
Depreciation
As at 1 January 2025 | 11,275
Provided during the period | 63,588
As at 31 December 2025 | 74,863
Net Book Value
As at 31 December 2025 | 283,034
As at 1 January 2025 | 135,551

5. Debtors

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Due within one year
Other debtors | 74,134 |  | 33,595
Due after more than one year
Trade debtors | - |  | 34,022
| 74,134 |  | 67,617

6. Creditors: Amounts Falling Due Within One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Net obligations under finance lease and hire purchase contracts | 16,335 |  | -
Trade creditors | 139,026 |  | 26,482
Other creditors | 9,500 |  | 30,726
Taxation and social security | 35,670 |  | 25,704
| 200,531 |  | 82,912

7. Creditors: Amounts Falling Due After More Than One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Net obligations under finance lease and hire purchase contracts | 54,450 |  | -

8. Share Capital

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 478 |  | 436

Page 4
Page 5
Glen Clova Scientific Limited
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2025
9. Reserves

| Share Premium | Fair value reserve | Profit and Loss Account
--- | --- | --- | ---
| £ | £ | £
As at 1 January 2025 | 3,010,293 | - | (847,229 )
Loss for the year and total comprehensive income | - | - | (2,441,633 )
Arising on shares issued during the period | 755,081 | - | -
Movements in fair value reserve | - | 33,915 | -
As at 31 December 2025 | 3,765,374 | 33,915 | (3,288,862 )

10. Ultimate Controlling Party
The company has no one ultimate controlling party.
11. Reclassification of Expenses
During the year, the management reviewed the classification of certain costs and determined that specific expenses previously included within Cost of Sales are more appropriately presented within Administrative Expenses, as they relate to general management and support functions rather than direct cost of production or service delivery.
Accordingly, comparative figures have been reclassified to ensure consistent presentation. This reclassification has no impact on total expenses, profit or net assets for the current or prior periods and represents a presentational adjustment only.
Page 5